DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tigan (Trimethobenzamide Hydrochloride) - Summary

 
 



TIGAN SUMMARY

Each 300-mg Tigan capsule for oral use contains trimethobenzamide hydrochloride equivalent to 300 mg.

Tigan  is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

 


See all Tigan indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Tigan (Trimethobenzamide)

Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. [2014]
may not be needed, although this has not been systematically studied... CONCLUSION: Our data suggest that trimethobenzamide helps reduce nausea/vomiting

A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. [2006.06]
BACKGROUND: Although various classes of medication are used to treat acute migraine in the emergency department (ED), no treatment offers complete pain relief without side effects or recurrence of headache. Consequently, even though several antiemetic medications as well as SQ sumatriptan have demonstrated efficacy and tolerability for the ED treatment of migraine, there remains a need for more effective parenteral therapies. Open-label studies suggest that the combination of trimethobenzamide and diphenhydramine (TMB/DPH) may provide effective relief in a high proportion of migraineurs. OBJECTIVE: To test the hypothesis that ED patients with acute migraine, given intramuscular TMB/DPH, would have a larger reduction in their pain scores than patients given SQ sumatriptan... CONCLUSIONS: SQ sumatriptan is probably superior to TMB/DPH for treating the pain of acute migraine at 2 hours. However, TMB/DPH was well-tolerated, efficacious, and relieved pain comparably to sumatriptan at 24 hours. TMB/DPH might have a role in select populations in which sumatriptan is contraindicated or likely to be ineffective.

more studies >>

Clinical Trials Related to Tigan (Trimethobenzamide)

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects [Completed]
This study will test the hypothesis that PF-06649751 with continuous co-administration of trimethobenzamide hydrochloride (TMB) with will be safe and well tolerated. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration.

Safety/Efficacy of Tigan� to Control Nausea/Vomiting Experienced During Apokyn� Initiation and Treatment [Completed]
The purposes of the study are to determine: i. To assess the efficacy of Tigan (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn (apomorphine) ii. To determine the optimal duration for continuation of Tigan following initiation of Apokyn® therapy iii. To assess the safety of Tigan® in combination with Apokyn® iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated concomitantly with and without Tigan®

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Completed]

Corneal Staining Associated With Daily Disposable Beauty Contact Lenses [Terminated]

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease [Recruiting]
This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration. Each cohort will aim to achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary endpoint is MDS-UPDRS part III.

more trials >>

Reports of Suspected Tigan (Trimethobenzamide) Side Effects

Drug Ineffective (3)Hyperventilation (3)Fibromyalgia (3)Breast Cancer (3)Drug Hypersensitivity (3)Disturbance in Attention (3)Pain (2)Reading Disorder (2)Suicidal Ideation (2)Fatigue (2)more >>


Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015